The design of the molecules was deliberately inspired by existing drugs. Donepezil, a mainstay Alzheimer’s therapy, owes much of its acetylcholinesterase-inhibiting power to its dimethoxy groups, while the anti-Parkinsonian drugs selegiline and rasagiline depend on a propargyl group to selectively and irreversibly inhibit monoamine oxidase B, thereby raising dopamine levels in the brain. A hybrid drug called TV-3326, which fuses features of rivastigmine and rasagiline, is undergoing clinical trials for its anti-apoptotic, neuroprotective effects in Alzheimer’s disease. Taking these structural lessons together, the Chandigarh group set out to create indanone derivatives bearing arylidene groups and, in several cases, a propargyloxy substituent, hoping to obtain multitarget-directed agents capable of attacking several pathological processes at once.

Synthesis of the compounds was accomplished through well-established base-catalysed aldol condensations. Mixing indanone or 5-methoxyindanone with the appropriate aldehyde and sodium hydroxide in methanol yielded the 2-arylidene indanones 1a through 1d. An interesting quirk emerged with the pyridyl aldehydes: rather than stopping at the simple aldol product, the reaction mixture underwent a further base-catalysed nucleophilic addition to form dimeric spiro compounds as the major products, whose structures were confirmed by nuclear magnetic resonance spectroscopy. For the propargyloxy series 3a through 3c, the researchers first prepared hydroxybenzylidene intermediates and then alkylated the phenolic oxygen with propargyl bromide in refluxing ethyl methyl ketone using potassium carbonate. Spectroscopic fingerprints, including the alkyne carbon-hydrogen stretch near 2112 wavenumbers in the infrared spectra and characteristic alkyne proton signals near 2.57 parts per million in the proton NMR, confirmed the successful installation of the propargyl ether moiety in each final compound.

To test anti-Parkinsonian activity, the team used mice treated with MPTP, a neurotoxin that damages dopaminergic neurons in the substantia nigra and produces the locomotor deficits characteristic of Parkinson’s disease. Mice received daily intraperitoneal injections of the test compounds at 20 milligrams per kilogram for seven days alongside the toxin, and their movement was assessed with an actophotometer and a rotarod apparatus. MPTP alone drastically reduced ambulation, rearing and rotarod performance, but co-treatment with the indanones significantly restored all three measures. The standout was compound 3b, the para-propargyloxybenzylidene indanone, which achieved an ambulation score of 229.66, rearing of 50.73 and a rotarod response of 249.33, actually exceeding the reference drug selegiline in rearing and rotarod performance. The remaining analogues also improved locomotion, though generally falling short of the standard drug.

For Alzheimer’s-like pathology, the researchers turned to rats injected with amyloid-beta peptide 1-42 directly into the hippocampus, a procedure that triggers glial activation, oxidative stress, chronic neuroinflammation and the loss of spatial learning and memory. Cognitive function was evaluated with the novel object recognition test and the elevated plus maze. Amyloid-treated rats showed a collapsed discrimination index and increased percentage of initial transfer latency, but seven days of treatment with the indanones significantly improved both measures. Here the most active compounds were the 5-methoxyindanones: compound 1d, bearing a para-methoxybenzylidene group, and compound 3c, carrying a meta-propargyloxy substituent, restored discrimination indices of 0.23 and 0.28 respectively, approaching but not surpassing the reference drug rivastigmine, which scored 0.38.

Biochemical analysis of brain homogenates revealed how the compounds were working at the cellular level. Neurotoxins such as MPTP and amyloid-beta disrupt the normal balance of oxidative markers, antioxidant enzymes and cholinergic signalling. Treatment with the indanones upregulated the antioxidant enzymes superoxide dismutase and glutathione peroxidase, downregulated lipid peroxidation as measured by malondialdehyde, scavenged excess reactive oxygen species, reduced nitric oxide levels and countered the overactivity of acetylcholinesterase. According to the authors, these biochemical shifts prevent calcium influx and mitochondrial depolarization, halting cell lysis and preserving neuronal membrane integrity, which ultimately translates into improved motor and cognitive function. Compound 3b again produced the greatest restoration of biochemical parameters in the MPTP mice, while 1d and 3c performed best in the amyloid-treated rats, mirroring the behavioural results.

Histopathological examination of brain sections under light microscopy provided visual confirmation of the protection. Brains from MPTP-treated mice showed degenerative changes in neurons due to oedema fluid, overactivation of astrocytes and microglia, and depletion of neuronal cells. In contrast, mice co-treated with compound 3b displayed far fewer neurodegenerative changes. Similarly, the hippocampi of amyloid-injected rats exhibited glial activation, chronic inflammation and apoptosis, while rats receiving compounds 1d or 3c showed much less neuroinflammation and no severe neuronal degeneration. These tissue-level observations aligned neatly with the behavioural and biochemical data, strengthening the overall evidence that the compounds genuinely shield neurons rather than merely masking symptoms.

Computational studies added a mechanistic dimension. An ADME analysis using the QikProp module of Schrödinger’s Maestro software showed that all the compounds obey Lipinski’s rules and possess predicted brain-to-blood partition coefficients above 0.3, indicating good penetration of the blood-brain barrier, an essential property for any central nervous system drug candidate. Molecular docking against the crystal structures of monoamine oxidase B, human acetylcholinesterase and beta-secretase revealed strong binding interactions. Compound 3b engaged MAO-B through pi-pi stacking with Trp-388 and polar contacts with Lys-296 and Val-294, closely mimicking the binding mode of the co-crystallized ligand safinamide. In acetylcholinesterase, compounds 1d and 3c formed pi-pi stacking interactions with Trp-286 and Tyr-337 within the enzyme’s 20-angstrom-deep gorge, while in beta-secretase they contacted Tyr-71, Tyr-198 and Phe-108 through a combination of stacking, hydrogen bonding and polar interactions.

Molecular dynamics simulations of 100 nanoseconds confirmed that these binding poses were stable over time. Root mean square deviation values stayed within the optimal range, and root mean square fluctuation values for individual amino acid side chains remained below 5 angstroms, indicating minimal conformational drift. Key interactions were retained throughout the simulations: compound 3b held its pi-pi stacking with Trp-388 of MAO-B for 41 percent of the simulation and its electrostatic contact with Lys-296 for 43 percent, while compound 1d maintained pi-pi stacking with Tyr-337 of acetylcholinesterase for 78 percent of the run and hydrogen bonding with Phe-295 for 75 percent. The consistency between docking and simulation lent computational credibility to the proposed mechanism of action.

The study’s structure-activity conclusions are clear: placing a propargyloxy group on the arylidene ring and adding a 5-methoxy substituent on the indanone nucleus both shape the pharmacological response, with the para-propargyloxy arrangement favouring anti-Parkinsonian activity and the 5-methoxy scaffold favouring cognitive protection. The authors caution that in vitro enzyme assays against MAO-B, acetylcholinesterase and beta-secretase will be needed to confirm the mechanism directly, and the path from rodent models to human therapy remains long. Nevertheless, the convergence of behavioural rescue, biochemical normalization, preserved brain histology and stable computational binding makes these indanone derivatives a compelling new platform for designing the next generation of multitarget neuroprotective drugs, offering a rare single-scaffold approach to two of the most devastating neurodegenerative diseases of our time.

Subject of Research: Neuroprotective evaluation of arylidene indanone derivatives in animal models of Parkinson's and Alzheimer's disease

Article Title: Experimental and computational insights into neuroprotective properties of arylidene indanone derivatives

Article References: Chandra, S., Singh, R., & Bansal, R. (2026). Experimental and computational insights into neuroprotective properties of arylidene indanone derivatives. Discover Chemistry, 3(1), Article 439. https://doi.org/10.1007/s44371-026-00885-1

Image Credits: AI Generated

DOI: 10.1007/s44371-026-00885-1

Keywords: indanone derivatives, neuroprotection, Parkinson's disease, Alzheimer's disease, MPTP mouse model, amyloid-beta, acetylcholinesterase, MAO-B, beta-secretase, molecular docking, oxidative stress, drug design

The clinical backdrop to the work is well established. Epidemiological studies have repeatedly shown that patients with Parkinson’s disease face a strikingly elevated risk of osteoporosis and osteoporotic fractures, a burden that exceeds what can be explained by poor mobility, falls, or age alone. Meta-analyses cited by the researchers indicate high rates of osteoporotic fracture in Parkinson’s disease, and cross-sectional clinical work has associated biomarkers such as serum uric acid with reduced bone mineral density in affected patients. Yet the molecular mechanisms that bind neurodegeneration to bone loss have remained murky. The Henan University team set out to interrogate that relationship experimentally, asking whether a single genetic factor—absence of ACE2—could simultaneously perturb dopaminergic neuron survival in the brain and bone homeostasis in the skeleton.

To do so, the researchers used a well-characterized mouse model of parkinsonism in which the neurotoxin MPTP, or 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, selectively destroys dopamine-producing neurons in the substantia nigra. Crucially, they crossed this challenge with mice lacking a functional ACE2 gene—specifically Ace2-null males, designated Ace2−/y—because ACE2 sits at the center of the protective arm of the renin-angiotensin system, converting angiotensin II into angiotensin-(1–7), a peptide with documented anti-inflammatory and neuroprotective actions. Previous studies from other groups and from the same team had shown that ACE2 activation mitigates behavioral deficits and neuroinflammation in chemically induced Parkinson’s models, and that the ACE2/Ang-(1–7)/Mas cascade strengthens bone structure and metabolism. The new study asked what happens when this protective factor is removed entirely under parkinsonian stress.

Behavioral testing revealed a clear aggravating effect. MPTP exposure significantly worsened motor dysfunction and depression-like behaviors in the mice, and the combination of MPTP toxicity with ACE2 deficiency produced a particularly severe pathological picture in the brain. Immunohistochemistry, Western blotting, and histopathological staining showed reduced activity of dopaminergic neurons and heightened microglial activation—the inflammatory response of the brain’s resident immune cells. At the molecular level, the researchers measured elevated levels of total α-synuclein, the misfolding-prone protein that defines Parkinson’s pathology, alongside increased abundance of Caspase-3 and Bax, two canonical executioners of programmed cell death. Together, these markers indicate that ACE2 loss intensifies both the protein aggregation burden and the apoptotic pressure on vulnerable neurons.

The bone findings were equally striking, and notably they emerged in parallel rather than secondarily. In the skeletal tissue of the Ace2-deficient mice, the team documented reduced abundance of total Wnt ligands, β-catenin, bone morphogenetic proteins (BMP), and insulin-like growth factor 1 (IGF-1), along with diminished phosphorylation ratios of the downstream kinases that transmit these signals. This matters because each of these cascades is a cornerstone of bone formation: Wnt/β-catenin signaling drives osteoblast differentiation and bone accrual, BMPs are potent inducers of bone formation used clinically in spine fusion and fracture repair, and IGF-1 couples muscle and bone metabolism through mTOR-dependent pathways. The researchers are careful to note that the parallel reduction of these signaling proteins suggests potential perturbation of the cascades rather than definitive proof of pathway failure, a distinction that reflects appropriate scientific caution.

In the opposite direction, ACE2 deficiency upregulated mediators of the RANKL/RANK/OPG axis, a triad that governs osteoclast formation and bone resorption. RANKL binding to RANK on osteoclast precursors drives the differentiation of bone-resorbing cells, while OPG acts as a soluble decoy receptor that restrains the process. Dysregulation of this axis tilts bone turnover toward net loss. Intriguingly, the same axis operates in the brain, where it has been identified as a critical inflammatory signaling system in ischemic injury, and Rho GTPases downstream of these pathways modulate osteoclast differentiation directly. The coordinated shift of this inflammatory skeletal axis in both brain and bone tissue under ACE2 deficiency is one of the study’s most suggestive observations, hinting at a common pathological language spoken by the two organs.

To move from candidate pathways to gene-level targets, the team turned to transcriptomics. They mined public GEO datasets and applied weighted gene co-expression network analysis, or WGCNA, a computational method that groups genes into modules based on correlated expression patterns and identifies the hub genes most central to disease-associated modules. This analysis pinpointed ten hub genes, including DNM1, which encodes dynamin 1, a protein essential for synaptic vesicle recycling; OCRL, a phosphatidylinositol phosphate phosphatase linked to the oculocerebrorenal syndrome; and OPA1, a mitochondrial fusion protein whose mutations cause dominant optic atrophy and which has been implicated in mitochondrial parkinsonism through stem cell modeling. The dysregulation of these genes was linked to synaptic dysfunction and inflammation—two processes squarely at the heart of Parkinson’s pathophysiology.

The team then evaluated whether these hub genes could serve as diagnostic biomarkers. Using receiver operating characteristic, or ROC, analysis on public single-disease transcriptome datasets for Parkinson’s disease and osteoporosis separately, they found that the core gene signatures achieved areas under the curve ranging from 0.683 to 0.981, indicating diagnostic accuracy that spans moderate to near-perfect discrimination. Functional enrichment of the core genes pointed to involvement in synaptic signaling, MAPK signaling, and the Rap1 and Ras pathways—small GTPase cascades that regulate cell proliferation, differentiation, and cytoskeletal dynamics in both neurons and bone cells. Such dual-diagnostic performance, if replicated in human cohorts, would suggest that a shared molecular signature underlies both conditions and could be exploited clinically to identify patients at risk of combined neurodegenerative and skeletal decline.

The authors are appropriately measured in their claims. They emphasize that these are preclinical findings obtained under short-term MPTP treatment in growing young male mice, meaning that the observed bone metabolic disturbance was transient and that the results may not translate directly to elderly human patients, in whom Parkinson’s disease typically manifests and in whom bone loss is chronic and sex-dependent. They also stress that the coordinated dysregulation observed in brain and bone is consistent with a bone-brain axis pathological phenotype, but that the current experimental design cannot confirm causal bidirectional cross-talk between the tissues. Distinguishing whether ACE2 deficiency independently damages both organs, or whether pathology in one propagates to the other—perhaps through circulating osteocalcin, sympathetic nervous system output, or inflammatory mediators—will require interventional studies that manipulate one tissue and measure the other.

Even with those caveats, the study offers a compelling framework and a set of concrete targets for follow-up. Restoring ACE2 activity or mimicking its product, angiotensin-(1–7), has already shown neuroprotective effects in experimental Parkinson’s models, including reduced α-synuclein expression through the NEAT1/miR-153-3p axis, and ACE2 activation has been reported to promote hippocampal neurogenesis via Wnt/β-catenin signaling. The present results raise the possibility that such therapies could carry a skeletal benefit as well, protecting against the osteoporosis that so often compounds the disability of Parkinson’s disease. The ten hub genes, meanwhile, provide a molecular shortlist for mechanistic validation, and their diagnostic AUC values justify testing in human blood or tissue datasets. As the bone-brain axis matures from a descriptive concept into a mechanistic research program, work like this demonstrates how a single molecule, studied across two organs at once, can illuminate disease connections that medicine has long observed clinically but struggled to explain at the level of genes and signaling pathways.

Subject of Research: ACE2-dependent molecular mechanisms linking Parkinson's disease neurodegeneration and bone metabolic alterations via the bone-brain axis

Article Title: ACE2 and Parkinsonism‑related bone metabolic alterations: signaling pathways and hub gene analysis

Article References: Liu, T., Ren, Y., Tian, X., & Wei, J. (2026). ACE2 and Parkinsonism‑related bone metabolic alterations: signaling pathways and hub gene analysis. Molecular Genetics and Genomics, 301(1), Article 185. https://doi.org/10.1007/s00438-026-02511-2

Image Credits: AI Generated

DOI: 10.1007/s00438-026-02511-2

Keywords: Parkinson's disease, ACE2, bone metabolism, bone-brain axis, osteoporosis, Wnt/beta-catenin signaling, RANKL/RANK/OPG, IGF-1, hub genes, WGCNA, alpha-synuclein, MPTP mouse model